HC Wainwright restated their buy rating on shares of Homology Medicines (NASDAQ:FIXX – Get Rating) in a research note published on Tuesday morning, PriceTargets.com reports. HC Wainwright also issued estimates for Homology Medicines’ Q4 2022 earnings at ($0.57) EPS, FY2022 earnings at ($1.86) EPS, Q1 2023 earnings at ($0.56) EPS, Q2 2023 earnings at ($0.56) EPS, Q3 2023 earnings at ($0.56) EPS, Q4 2023 earnings at ($0.56) EPS, FY2023 earnings at ($2.24) EPS, FY2024 earnings at ($1.24) EPS, FY2025 earnings at ($0.39) EPS and FY2026 earnings at $0.28 EPS.
A number of other equities research analysts have also weighed in on FIXX. BTIG Research lowered their price objective on shares of Homology Medicines from $29.00 to $12.00 and set a buy rating for the company in a report on Tuesday, August 16th. Robert W. Baird decreased their price objective on Homology Medicines from $10.00 to $9.00 and set an outperform rating on the stock in a report on Wednesday, August 31st. Royal Bank of Canada lowered their target price on Homology Medicines from $4.00 to $3.00 and set a sector perform rating for the company in a research note on Friday, November 11th. Chardan Capital reduced their price target on Homology Medicines from $10.00 to $8.00 and set a buy rating on the stock in a research report on Thursday, November 17th. Finally, Credit Suisse Group decreased their price target on Homology Medicines to $2.10 in a research note on Wednesday, November 16th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Homology Medicines has a consensus rating of Moderate Buy and an average target price of $8.57.
Homology Medicines Trading Down 10.0 %
Shares of NASDAQ FIXX opened at $1.62 on Tuesday. The stock’s 50-day moving average is $1.56 and its 200 day moving average is $1.93. The stock has a market cap of $93.12 million, a price-to-earnings ratio of -16.20 and a beta of -0.19. Homology Medicines has a 1-year low of $1.30 and a 1-year high of $5.34.
Hedge Funds Weigh In On Homology Medicines
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders.
- Get a free copy of the StockNews.com research report on Homology Medicines (FIXX)
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.